Lentinula edodes (shiitake mushroom) mycelia have been investigated for their potential role in supporting cardiovascular health, including hypertension (high blood pressure). The scientific evidence supporting their use is limited but growing, primarily based on preclinical (animal and laboratory) studies rather than robust human clinical trials.

Several in vitro and animal studies suggest that compounds found in L. edodes mycelia—such as eritadenine, beta-glucans, and sterols—may contribute to blood pressure regulation. Notably, eritadenine has been shown in animal models to reduce blood cholesterol levels and may influence lipid metabolism, an indirect factor in hypertension. Some studies also report mild antihypertensive effects, potentially due to improved endothelial function and reduced vascular resistance.

However, direct evidence from human clinical trials is sparse. While shiitake mushrooms have a long history of culinary and medicinal use, traditional uses focus more on immune support and general health, rather than specifically targeting hypertension. Existing human data are mostly preliminary, and more rigorous, large-scale studies are needed to confirm efficacy and safety.

In summary, L. edodes mycelia show some promise based on early scientific findings, but current evidence is modest (rated 2 out of 5) and insufficient for conclusive recommendations. Their use for hypertension remains experimental, and individuals should consult healthcare professionals before relying on them for blood pressure management.